John A. Vernon

1.9k total citations
53 papers, 1.2k citations indexed

About

John A. Vernon is a scholar working on Economics and Econometrics, Pharmacology and Management of Technology and Innovation. According to data from OpenAlex, John A. Vernon has authored 53 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 46 papers in Economics and Econometrics, 12 papers in Pharmacology and 7 papers in Management of Technology and Innovation. Recurrent topics in John A. Vernon's work include Pharmaceutical Economics and Policy (41 papers), Health Systems, Economic Evaluations, Quality of Life (22 papers) and Innovation Policy and R&D (19 papers). John A. Vernon is often cited by papers focused on Pharmaceutical Economics and Policy (41 papers), Health Systems, Economic Evaluations, Quality of Life (22 papers) and Innovation Policy and R&D (19 papers). John A. Vernon collaborates with scholars based in United States. John A. Vernon's co-authors include Joseph H. Golec, Antonio J. Trujillo, Rexford E. Santerre, Barbara A. DeBuono, Sara Rosenbaum, Carmelo Giaccotto, Joseph P. Cook, Joseph A. DiMasi, Richard Manning and Thomas A. Abbott and has published in prestigious journals such as Journal of Agricultural and Food Chemistry, The Annual Review of Pharmacology and Toxicology and Journal of Financial and Quantitative Analysis.

In The Last Decade

John A. Vernon

51 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
John A. Vernon United States 17 703 271 142 134 131 53 1.2k
Ge Bai United States 22 798 1.1× 623 2.3× 86 0.6× 62 0.5× 16 0.1× 146 1.8k
Jorge Mestre-Ferrándiz United Kingdom 15 653 0.9× 230 0.8× 64 0.5× 39 0.3× 57 0.4× 73 1.4k
Alessandra Ferrario United Kingdom 15 648 0.9× 159 0.6× 130 0.9× 77 0.6× 30 0.2× 40 1.2k
Jillian Clare Köhler Canada 22 466 0.7× 162 0.6× 91 0.6× 164 1.2× 83 0.6× 82 1.2k
Valérie Paris France 11 472 0.7× 231 0.9× 92 0.6× 64 0.5× 23 0.2× 27 651
Alexandra Cameron Switzerland 8 924 1.3× 116 0.4× 91 0.6× 319 2.4× 71 0.5× 11 1.3k
Margaret Ewen Switzerland 16 1.2k 1.7× 173 0.6× 83 0.6× 412 3.1× 67 0.5× 36 1.7k
Michael F. Furukawa United States 26 689 1.0× 906 3.3× 103 0.7× 29 0.2× 56 0.4× 56 2.3k
Andrea M. Sisko United States 20 892 1.3× 819 3.0× 65 0.5× 63 0.5× 11 0.1× 25 1.8k
Sotiris Vandoros United Kingdom 19 495 0.7× 427 1.6× 119 0.8× 72 0.5× 53 0.4× 51 1.1k

Countries citing papers authored by John A. Vernon

Since Specialization
Citations

This map shows the geographic impact of John A. Vernon's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John A. Vernon with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John A. Vernon more than expected).

Fields of papers citing papers by John A. Vernon

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John A. Vernon. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John A. Vernon. The network helps show where John A. Vernon may publish in the future.

Co-authorship network of co-authors of John A. Vernon

This figure shows the co-authorship network connecting the top 25 collaborators of John A. Vernon. A scholar is included among the top collaborators of John A. Vernon based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John A. Vernon. John A. Vernon is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Vernon, John A., et al.. (2012). Measuring the Patient Health, Societal and Economic Benefits of US Pediatric Therapeutics Legislation. Pediatric Drugs. 14(5). 283–294. 6 indexed citations
2.
Cook, Joseph P., Graeme K. Hunter, & John A. Vernon. (2010). Generic Utilization Rates, Real Pharmaceutical Prices, and Research and Development Expenditures. National Bureau of Economic Research. 2 indexed citations
3.
Trujillo, Antonio J., Thomas A. Mroz, Claudia Piras, John A. Vernon, & Gustavo Ángeles. (2010). Determinants of Gender Differences in Health among the Elderly in Latin America. World health & population. 11(3). 24–43. 4 indexed citations
4.
Vernon, John A., Robert B. Goldberg, & Joseph H. Golec. (2009). Economic Evaluation and Cost-Effectiveness Thresholds. PharmacoEconomics. 27(10). 797–806. 14 indexed citations
5.
Golec, Joseph H. & John A. Vernon. (2009). Financial risk of the Biotech Industry versus the Pharmaceutical Industry. Applied Health Economics and Health Policy. 7(3). 155–165. 12 indexed citations
6.
Vernon, John A., Michael Payette, & Abhishek Chatterjee. (2009). Social Welfare and Adolescent Vaccination Programs in the United States: The Economic Opportunities for a Systematic Expansion. Social Work in Public Health. 24(5). 414–445. 5 indexed citations
7.
Vernon, John A., Joseph H. Golec, & Joseph A. DiMasi. (2009). Drug development costs when financial risk is measured using the Fama–French three‐factor model. Health Economics. 19(8). 1002–1005. 68 indexed citations
8.
Golec, Joseph H. & John A. Vernon. (2009). What's the. SSRN Electronic Journal. 26 indexed citations
9.
Golec, Joseph H. & John A. Vernon. (2008). Measuring US Pharmaceutical Industry R&D Spending. PharmacoEconomics. 26(12). 1005–1017. 5 indexed citations
10.
Cook, Joseph P., John A. Vernon, & Richard Manning. (2008). Pharmaceutical Risk-Sharing Agreements. PharmacoEconomics. 26(7). 551–556. 62 indexed citations
11.
Vernon, John A., Antonio J. Trujillo, Sara Rosenbaum, & Barbara A. DeBuono. (2007). Low Health Literacy: Implications for National Health Policy. Journal of Agricultural and Food Chemistry. 63(8). 2296–304. 165 indexed citations
12.
Santerre, Rexford E. & John A. Vernon. (2007). Ownership Form and Consumer Welfare: Evidence from the Nursing Home Industry. INQUIRY The Journal of Health Care Organization Provision and Financing. 44(4). 381–399. 9 indexed citations
13.
Santerre, Rexford E., John A. Vernon, & Carmelo Giaccotto. (2006). THE IMPACT OF INDIRECT GOVERNMENT CONTROLS ON U.S. DRUG PRICES AND R&D. Cato Journal. 26(1). 143–158. 8 indexed citations
14.
Santerre, Rexford E. & John A. Vernon. (2006). Assessing Consumer Gains from a Drug Price Control Policy in the United States. Southern Economic Journal. 73(1). 233–245. 12 indexed citations
15.
Vernon, John A., et al.. (2006). The Economics of Pharmaceutical Price Regulation and Importation: Refocusing the Debate. American Journal of Law & Medicine. 32(2-3). 175–192. 13 indexed citations
16.
Trujillo, Antonio J., et al.. (2005). The Impact of Subsidized Health Insurance for the Poor: Evaluating the Colombian Experience Using Propensity Score Matching. International Journal of Health Care Finance and Economics. 5(3). 211–239. 104 indexed citations
17.
Santerre, Rexford E. & John A. Vernon. (2005). Testing for Ownership Mix Efficiency: The Case of the Nursing Home Industry. National Bureau of Economic Research. 7 indexed citations
18.
Abbott, Thomas A. & John A. Vernon. (2005). The Cost of US Pharmaceutical Price Reductions: A Financial Simulation Model of R&D Decisions. RePEc: Research Papers in Economics. 1 indexed citations
19.
Vernon, John A., et al.. (2005). Mathematical Modeling and Pharmaceutical Pricing: Analyses Used to Inform In-Licensing and Developmental Go/No-Go Decisions. Health Care Management Science. 8(2). 167–179. 11 indexed citations
20.
Vernon, John A.. (2003). Price regulation, capital market imperfections, and strategic R&D investment behavior in the pharmaceutical industry: Consequences for innovation. 17(3). 292–6. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ge Bai Breakdown of academic impact, for papers by Jorge Mestre-Ferrándiz Breakdown of academic impact, for papers by Alessandra Ferrario Breakdown of academic impact, for papers by Jillian Clare Köhler Breakdown of academic impact, for papers by Valérie Paris Breakdown of academic impact, for papers by Alexandra Cameron Breakdown of academic impact, for papers by Margaret Ewen Breakdown of academic impact, for papers by Michael F. Furukawa Breakdown of academic impact, for papers by Andrea M. Sisko Breakdown of academic impact, for papers by Sotiris Vandoros
Rankless by CCL
2026